For most people, the recommended usage period is 12 weeks
Key Takeaways Cagrilintide is a long-acting amylin analogue with clinical trial doses ranging from 0.3 mg to 4.5 mg weekly, while retatrutide is a triple agonist studied at 4 mg, 8 mg, and 12 mg weekly doses No published clinical trials currently exist evaluating the cagrilintide dosage with retatrutide combination, making any combined use experimental and off-label Both peptides work through different mechanismscagrilintide activates amylin receptors while retatrutide targets GIP, GLP-1, and glucagon receptorssuggesting potential complementary effects Gastrointestinal side effects (nausea, vomiting) occur in 60-80% of participants at higher doses for both compounds, raising concerns about additive effects when combined Proper dose escalation protocols spanning 8-20 weeks are critical for tolerability and adherence in peptide-based metabolic therapies Understanding Cagrilintide: Mechanism and Dosage Fundamentals What Is Cagrilintide
doi: 10.1016/j.aquaculture.2024.740715 238 QiX
Additionally, I discuss the biology of hangovers and describe science-based strategies to mitigate the severity of a hangover
FIGURE 1 3.2 Daphnetin attenuated oxidative stress of diabetes cognitive dysfunction rats As shown in Figure 2, STZ-treated caused oxidative stress in rat brain, which increased the MDA content and GSSH content, and reduced the levels of SOD, CAT, GSH, Gpx and TAC, while daphnetin-treated inhibited these changes in oxidative stress-related medicators, which indicated that daphnetin could mitigate oxidative stress of diabetes cognitive dysfunction rats
